Bioavailability of phenolics from olive leaf extract.
- Conditions
- pharmacokinetics of oleuropein metabolites
- Registration Number
- NL-OMON21153
- Lead Sponsor
- BioActor BV
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 16
Inclusion Criteria
GROUP 1:
1. Premenopausal women between 18 and 75 years old;
Exclusion Criteria
1. Clinically significant abnormal liver functioning (serum alanine and aspartate aminotransferase);
2. Clinically significant abnormal serum creatinin;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Concentrations of oleuropein metabolites in plasma and urine over 24h upon single dose administration of olive leaf extract standardized on oleuropein.
- Secondary Outcome Measures
Name Time Method 1. Differences in pharmacokinetic profiles between pre- and postmenopausal women;<br /><br>2. Activity of circulating oleuropein metabolites towards bone metabolism markers in ex vivo assay.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the pharmacokinetic profiles of oleuropein metabolites in NL-OMON21153 BioActor BV trial?
How does olive leaf extract bioavailability compare to dietary phenolics in metabolic syndrome patients?
Which CYP enzymes influence oleuropein metabolite absorption and excretion in BioActor BV studies?
What adverse effects are associated with high-dose olive leaf extract in BioActor BV pharmacokinetic trials?
Are there synergistic effects when combining olive leaf extract with other polyphenols in cardiovascular health?